Celgene Corp. shares rose 1% in premarket trade Thursday, after the company reported positive results for a late-stage trial of a treatment for multiple myeloma in patients who are not candidates for a stem-cell transplant. Celgene said data from the study of continuous REVLIMID (lenalidomide) in combination with dexamethasone showed the treatment met its primary endpoint. The findings have been published in the New England Journal of Medicine. Celgene shares have gained 12.4% in the year so far, outperforming the S&P 500 which is up 8.2%.

Copyright © 2014 MarketWatch, Inc.